FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely neurology, and is applicable for treating damaged remitting multiple sclerosis. That is ensured by introducing autologous regulatory T-cells of CD4+CD25+Foxp3+ grown ex vivo at 4.5-5.5 mln cells per 1 kg of a patient's body weight in the remitting multiple sclerosis remission stage.
EFFECT: using the given method provides increasing of CD4+CD25+Foxp3+ regulatory T-cells by 2 times and more and maintaining a normal level which enables prolonging the remission stage up to 12 months.
13 dwg, 3 ex, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING MULTIPLE SCLEROSIS | 2001 |
|
RU2199339C2 |
| METHOD OF TREATING MULTIPLE SCLEROSIS | 2008 |
|
RU2390334C1 |
| METHOD FOR DETERMINING PATHOLOGICAL PROCESS ACTIVITY IN PATIENTS WITH MULTIPLE SCLEROSIS | 2016 |
|
RU2613908C1 |
| METHOD OF PATHOLOGICAL PROCESS ACTIVITY DETERMINING IN PATIENTS WITH MULTIPLE SCLEROSIS | 2019 |
|
RU2694614C1 |
| METHOD OF HUMAN REGULATORY CD4CD25FOXP3T-CELL ENRICHMENT ex vivo | 2010 |
|
RU2437933C1 |
| PEPTIDE FROM THE COMPOSITION OF THE IMMUNOGLOBULIN HUMAN HEAVY CHAIN, SUITABLE FOR TREATMENT OF MULTIPLE SCLEROSIS | 2016 |
|
RU2646817C1 |
| METHOD OF PREDICTING STAGE OF MULTIPLE SCLEROSIS TAKING INTO ACCOUNT INDICATORS OF IMMUNOLOGICAL STATUS | 2023 |
|
RU2811481C1 |
| APPLICATION OF PROBIOTIC STRAIN OF ENTEROCOCCUS FAECIUM L-3 MICROORGANISM FOR NEURODEGENERATIVE DISEASES TREATMENT | 2014 |
|
RU2642246C2 |
| METHOD FOR PRODUCTION OF POLYCLONAL T-CELL VACCINE USEFUL IN TREATMENT OF IMMUNOLOGICAL DISORDERS | 2004 |
|
RU2277422C2 |
| COMPOSITIONS FOR TREATMENT OF DISSEMINATED SCLEROSIS | 2008 |
|
RU2492234C2 |
